Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) - Fasching, Peter; Bardia, A.; Nusch, A.; Jerusalem, G.; Chan, A.; El Saghir, N.; Alba, E.; Im, S-A.; Janni, W.; Chandiwana, D.; Lanoue, B.; Thuerigen, A.; et al. (ANNALS OF ONCOLOGY, 2020)
CRIS-Team WoS Importer:2020-10-30